Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC + CD4 + cell levels: a surrogate marker candidate of HIV-induced intestinal damage
4IMVA - U1184 - Immunologie des Maladies Virales et Autoimmunes (Site de l'Hôpital de Bicêtre - Faculté de Médecine Paris Sud - 63 rue Gabriel Péri 94276 Le Kremlin-Bicêtre Cedex.
Site du CEA de Fontenay-aux-Roses - 10, route du Panorama - BP 6 - 92265 Fontenay-aux-Roses. - France)
Abstract : Combined anti-retroviral therapy (cART) transformed HIV-1 from a deadly disease into a chronic infection, but does not cure HIV infection. It also does not fully restore HIV-induced gut damage unless administered extremely early after infection. Additional biomarkers are needed to evaluate the capacity of therapies aimed at HIV remission/cure to restore HIV-induced intestinal immune damage and limit chronic inflammation. Herein, we aimed to identify a systemic surrogate marker whose levels would reflect gut immune damage such as intestinal Th17 cell loss starting from primary HIV-1 infection.
https://hal-pasteur.archives-ouvertes.fr/pasteur-01880368 Contributor : Marie-Christine VougnyConnect in order to contact the contributor Submitted on : Monday, September 24, 2018 - 4:59:00 PM Last modification on : Wednesday, June 15, 2022 - 4:15:27 AM Long-term archiving on: : Tuesday, December 25, 2018 - 4:03:03 PM
Mickaël Ploquin, Armanda Casrouge, yoann Madec, Nicolas Noël, Béatrice Jacquelin, et al.. Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC + CD4 + cell levels: a surrogate marker candidate of HIV-induced intestinal damage. Journal of the International AIDS Society, BioMed Central (2008-2012) ; International Aids Society (2008-) ; Wiley (2017-), 2018, 21 (7), pp.e25144. ⟨10.1002/jia2.25144⟩. ⟨pasteur-01880368⟩